using up to double extrastimuli at the right ventricular apex and right ventricular outflow tract (RVOT). The coupling intervals of the extrastimuli were kept at more than 200 ms. The endpoint was either the reproducible induction of VF or completion of the pacing protocol.
Drug Challenge Test
Sodium channel blockers, 10 mg/kg of procainamide (Sabex Pharm, Canada), or 0.5 mg/kg of pilsicainide (Suntory Pharm, Japan), were intravenously administered to investigate the ST-segment changes.
Right Ventriculography (RVG) and Coronary Angiography (CAG)
RVG was performed with a 6 Fr pigtail catheter (Boston Scientific, USA) and Ultravist 370 (Schering, Germany) at end-inspiration. We used anterioposterior and lateral projections (30 frames/s, 512×512 matrix).
Coronary spasm during CAG was induced with intracoronary administration of up to 0.2 mg of ergonovine maleate (Jeil Pharm, Korea) in patients with chest pain or tightness.
Endomyocardial Biopsy
Endomyocardial biopsies were performed from the right side of the interventricular septum and RVOT using 5.5 Fr forceps (Biopsy-forceps, Cordis, USA) until approximately 5-7 specimens of adequate size were obtained.
Treatment With Follow-up
We recommended implantation of a cardioverter defibrillator (ICD) for high-risk patients and observation only was scheduled for low-risk patients. All the patients regularly visited the outpatient clinic and were followed-up. Tables 1 and 2 show the clinical characteristics of the 14 patients (mean age 44±10 (range 25-64); all male). Eight patients had the type 1 coved pattern and 6 had the type 2 saddle-back pattern. Eleven patients had a history of atypical chest pain or tightness and 2 (Nos. 2 and 9) had survived cardiac arrests that had occurred while they were at rest. Another patient had a history of agonal respirations with an altered mentality at midnight (No. 12). Only 1 patient (No. 3) had a family history of premature SD. None of the patients had abused drugs or were taking any medication at the time of the study. The physical examinations were normal in all patients, with no evidence of cardiac or extracardiac disease. The chest X-ray, routine laboratory and thyroid tests were normal in all patients.
Results

Clinical Characteristics
Twelve-Lead ECG and Drug Challenge Test
The 12-lead ECGs (Fig 1) revealed sinus rhythm in all the patients. The PR interval, QT interval, and rate-corrected QT interval were all within normal limits. The ECG from patient No. 2 showed an epsilon wave in lead V1. Four patients (Nos. 1-3 and 12) had intermittent RBBB with STsegment elevation in the right precordial leads during follow-up. In addition, the ECG of patients Nos. 2 and 9 exhibited augmentation of the ST elevation after the administration of sodium-channel blockers (Fig 2) .
CAG
CAG with and without intracoronary administration of ergonovine was normal in all patients.
EPS and SAECG
VF was induced in 5 patients (36%), 9 patients (82%) had positive late potentials, and 2 patients (Nos. 7 and 12) had both induced VF and positive late potentials.
Morphological and Pathological Abnormalities
Routine 2-D echocardiography was normal in all patients, but RVG was abnormal in 4 patients (29%) (Fig 3) . On endomyocardial biopsy 7 patients (Nos. 3, 4, 7, 9-12) showed nonspecific myocyte degeneration with inflammatory cell infiltration suggesting cardiomyopathy. In particular, 2 patients (Nos. 3 and 4) showed marked fatty and fibrofatty replacement consistent with ARVC (Fig 4) .
Treatment With Follow-up
The 3 patients (Nos. 2, 9 and 12) who presented with cardiac arrest or syncope were recommended for ICD, but only 1 underwent the procedure (No. 12); the other 2 refused. Of the patients with atypical chest pain or tightness, those with induced VF by EPS were treated withblockers and those without inducible VF were followed up without medication. All except 2 patients (Nos. 1 and 12) had a regular follow-up without events. One patient (No. 1) died of an unrelated accident and another (No. 12) had 10 episodes of VF with appropriate ICD shocks (Fig 5) .
Discussion
In 1992, the Brugada brothers described 8 patients with typical ST-segment elevation in the right precordial leads and cardiac arrest from idiopathic VF, which is now known as Brugada syndrome. 1, 9 Because the ST-segment elevation and VF in those patients could not be explained by electrolyte disturbances, ischemia or structural heart disease, a pure electrical disease was suggested as the mechanism. A cardiac sodium-channel gene mutation found in some of these patients further supported that concept. 10 However, in most series the assumption of structurally normal hearts in those patients has not been based on a detailed pathological examination, but rather on the clinical features and routine cardiac imaging modalities. 1, 9 Some studies even demonstrated fibrofatty replacement of the right ventricular myocardium. 2, 3, 11 Recently, histologic abnormalities have been detected in patients with Brugada syndrome, 5 and right ventricular fibrosis with localized conduction delay was found in the explanted heart of a patient with Brugada syndrome. 6 However, despite these repeated suggestions of structural abnormalities, the relationship between the typical ECG pattern and the pathologic changes is still unclear because the study populations have been small and some have shown a different clinical course to that of typical Brugada syndrome. 12 Both Brugada syndrome and ARVC are not rare in Korea 7,13 and our previous study 7 showed that many patients with ARVC died during their sleep or at rest, which is similar to Brugada syndrome. Therefore, we wanted to assess whether there is underlying organic heart disease in patients with Brugada-type ECGs.
In the present study there were histologic abnormalities in a substantial number of patients with ST-segment elevation in the right precordial leads. Two patients (Nos. 2 and 9) had documented VF with cardiac arrest and a Brugada type 1 ECG, with a positive drug provocation test, and 1 patient (No. 12) with a type 1 ECG had a clinical history of agonal respirations associated with altered consciousness and documented VFs on stored electrograms in the ICD during follow-up. Therefore, these 3 patients could be diagnosed as definite cases of Brugada syndrome. However, the endomyocardial specimens from 2 of them (Nos. 9 and 12) showed underlying cardiomyopathy, which is similar to the results from a previous study. 2 Another thing to consider is that the ECG of patient No. 2 showed an epsilon wave, 
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which is attributed to the presence of delayed activation in the RV and is observed in up to 30% of patients with ARVC. 14 Other 5 patients with insufficient ECG findings and/or history to be diagnosed with Brugada syndrome also had wall motion and/or histologic abnormalities. Although Tada et al failed to reveal any abnormalities on endomyocardial biopsy, 11 we found histologic abnormalities in 50% of the cases. We obtained samples from many areas of the myocardium, which may have influenced the results. The recent study by Frustaci et al showed abnormal histologic findings in all of their typically symptomatic patients. 5 These differences in results may be partly explained by the small number of typically symptomatic patients in the present study.
Some patients with Brugada syndrome are positive for late potentials, 15 which are regarded as representative of delayed conduction, but their cause in this electrical disease has not been easy to explain. Recently, Nagase et al demonstrated an 'epicardial abnormality' in the RVOT, which may help to explain late potentials in Brugada syndrome, 16 but in the present study 9 of 11 patients who underwent SAECG had late potentials, and 5 of those 9 had an 'endocardial abnormality' on the endomyocardial biopsy. This difference in results suggests that both epicardial and endocardial abnormalities may be involved in the pathogenesis of the ST-segment elevation in the right precordial leads, an hypothesis that is supported by Coronel et al who showed that localized epicardial conduction delay in the RVOT was associated with ST-segment elevation in the right precordial leads. 6 Our results also suggest that positive late potentials fulfilling all 3 parameters strongly reflect underlying pathological changes. Among the 9 patients who satisfied all 3 parameters of late potentials, 5 had wall motion abnormalities and/or pathologic findings on endomyocardial biopsy. VF was induced in 5 patients and 2 (Nos. 3 and 4) of them had fibrofatty infiltration of the myocardium suggesting ARVC. Of the 3 patients with documented VF or syncope, VF was inducible in 1, and late potentials were positive in 2. Only 1 patient (No. 12) had all the abnormal findings: positive history, inducible VF, positive late potentials, and pathologic findings compatible with cardiomyopathy.
Traditionally, wall motion abnormalities have been regarded as evidence of organic heart disease. Previous studies have reported wall motion abnormalities in patients with ST-segment elevation in the right precordial leads, [2] [3] [4] 11 although routine 2-D echocardiography may fail to detect the subtle wall motion abnormalities in such patients. In our study, we detected wall motion abnormalities in 4 (29%) of 14 patients by RVG, but 2-D echocardiography did not reveal these abnormalities in any of the patients, confirming the well-known limitation of 2-D echocardiography to detect subtle abnormalities in the right ventricle. 5 The Brugada-type ECG pattern is classified as type 1, 2 or 3 according to the ST-T configuration and ST-segment elevation. 17 Patients with the type 1 pattern are considered to be at high risk for an adverse prognosis, whereas those with a type 2 or 3 pattern are likely to have a more benign course In our study, 1 (No. 12) of 3 patients who have experienced cardiac arrest or syncope was treated with an ICD. In addition to spontaneous ST-segment elevation and a history of syncope, the change in the ST-segment in the right precordial leads from a nondiagnostic to typical coved-type pattern after a sodium-channel blockade has been reported to be helpful for diagnosing and risk stratification for Brugada syndrome in survivors of cardiac arrests and their relatives. [18] [19] [20] However, more recently it has been shown that the drug provocation test may be negative in up to 80% of asymptomatic patients with normal resting ECG 20 and the response to sodium-channel blockade would not be specific for the Brugada syndrome but could be positive in other conditions such as cardiomyopathy and myocarditis. 5 In the present study, even with this limitation, the drug provocation tests in patients Nos. 2 and 9 revealed an augmented ST-segment elevation of more than 1 mm from the baseline ECG and we were able to obtain a pathological confirmation in 1 of them (No. 9).
The endomyocardial specimens from patients Nos. 3 and 4 showed fibrofatty infiltration suggesting ARVC. Patient No. 4 had both an aneurysm in the right ventricle and fibrofatty infiltration of the myocardium, which were enough to make a diagnosis of ARVC according to the Task Force Criteria. 21 However, patient No. 3 could not satisfy the Task Force Criteria although the biopsy specimens showed typical fibrofatty infiltration and there was a family history of premature SD. Tada et al reported that ARVC might underlie the cardiac manifestation of Brugada syndrome. 11 The Brugada-like ECG pattern with wall motion abnormalities reported here could not be explained by other causes, such as ischemia or conduction abnormalities, as suggested by Brugada et al. 22 The present study was designed to demonstrate wall motion and histologic abnormalities in both typically and atypically symptomatic patients with ST-segment elevation in the right precordial leads. Our findings suggest that STsegment elevation in the right precordial leads may reflect an underlying pathologic process in the right ventricle and that some pathological process may also exist in patients who have been diagnosed as so-called Brugada syndrome. Therefore, it is prudent to exclude all other organic heart diseases before making a diagnosis of Brugada syndrome. Further studies are needed to enhance our understanding of this complex syndrome.
Study Limitations
The major limitation was the lack of typical symptoms in most of the patients. Second, a genetic analysis was not available. However, sodium-channel mutations have been identified in only a small portion of patients 18 and these mutations per se may not exclude an underlying organic heart disease. 5, 23 
Conclusion
Wall motion and/or histologic abnormalities of the right ventricle were found in more than half of the patients with ST-segment elevation in the right precordial leads, which suggests that the Brugada-type ECG pattern may reflect underlying cardiomyopathy.
